Nuvectis Pharma price to book ratio NVCT
Market value divided by the book value of the company's net assets, since 2022.
- Today, Nov 2, 2026
- 68.8×
- 4-year median
- 10.1×
- Against its 4-year history
- 96th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 4.9× to 87.9×
- Peer median
- 2.6×
Nuvectis Pharma's price to book ratio is 68.8× as of Nov 2, 2026.
That is above its 4-year median of 10.1×, higher than on 96% of days in the last 4 years.
Over that time it ranged from 4.9× in Nov 2022 to 87.9× in Sep 2026.
The median for 10 large drugmakers of a similar size is 2.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 68.8× | 8.7× | 87.9× |
| 2025 | 8.3× | 6.4× | 25.3× |
| 2024 | 9.2× | 6.9× | 19.0× |
| 2023 | 8.7× | 5.3× | 23.6× |
| 2022 | 5.4× | 4.9× | 16.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Nuvectis Pharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| NVCTNuvectis Pharma | 68.8× |
| ZVRAZevra Therapeutics | 2.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| PBYIPuma Biotechnology | 3.8× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| ARVNArvinas | 0.9× |
| CRMDCorMedix | 0.9× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| ANABAnaptysbio | 132× |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Nuvectis Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.